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Abstract 
Schizophrenia is a worldwide public health problem that requires a lot of personal and economic costs. 
Schizophrenia affects approximately 1% of the world's population. Anti-psychotic drug used in the treatment of 
schizophrenia have varying pharmacologic properties, first-generation antipsychotic Drugs such as neuroleptics 
is due to neurologic side effects equation. The second generation of antipsychotics or newer fewer neurological 
effects. In-depth research related to the use of antipsychotics, especially on the improvement of positive 
symptoms in schizophrenic patients are still very few women. methods; This research is an experimental study, 
the two forms of group pretest posttest design, which uses a questionnaire Positive and Negative Syndrome Scale 
(PANSS) is a valid measurement tool to assess the severity of symptoms experienced by patients with 
schizophrenia and an assessment of the output terapeutik. Kriteria Inclusion: Female Patients , age 15- 55 years, 
Body Mass Index from 18.50 to 24.99, have the same severity, acute phase, Exclusive criteria; hypersensitivity 
to quetiapine or haloperidol,komorbiditas pregnant and general medical illness, organic mental disorder or 
disturbance other psychiatric systolic blood pressure <100 mmHg. Of the study obtained for the largest 
proportion of the study subjects quetiapine group was aged 15-24 years, while for the 45-55 age group. 
haloperidol significantly different on demographic factors; age, occupation, marital status, and the educational 
status.Has the significant differences in scores on the PANSS positive scale and the third week, fourth drug 
intervention using either quetiapine or haloperidol (P<0.05). The proportion of the largest studies on the subject 
of female schizophrenic patients grouped quetiapine is aged 15-24 years and 45-55 years, while haloperidol 
obtained difference scores on the PANSS scale significantly positive drug intervention on the day the third and 
fourth. 
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1. Introduction 
Schizophrenia is a common health problem worldwide that require a lot of personal and economic costs. 
Schizophrenia affects approximately 1% of the world population. If the schizophrenia spectrum disorders 
included in the estimation of prevalence, the number of people affected increased by about 5%. Anti-psychotic 
drug used in the treatment of schizophrenia has pharmacological properties that vary, but all have the capacity as 
an antagonist at the post-synaptic dopamine receptors in the brain. The first-generation antipsychotic drugs are as 
neuroleptics because equation neurologic side effects. The second generation or later of antipsychotics fewer 
neurological effects and more as anti-psychotic atipikal.1-4 
Quetiapine reported in short-term studies (6 weeks) were able to lower PANSS score of 18.7 points, while 
haloperidol decrease PANSS score of 22.1 poin.5 In another study also mentioned the high dose (750mg / day) 
quetiapine and haloperidol (12 mg / day) were given to 286 patients hospitalized may reduce positive symptoms 
for 6 weeks penelitian.6 Siti Nurul reported that out of 20 people (16 men and 4 women) patients who have 
received quetiapine and an assessment on the third day showed a mean score of the PANSS positive sub-scale of 
30.6 (SD 3.3). In patients who have been given haloperidol (15 men and 5 women) showed a mean score of the 
PANSS subscales positive at 29.9 (SD3,2) value of P = 0.495. There is no change in PANSS subscales.7 
 
2. Subject and Methods 
This study was approved by the Research Ethics Committee of Medical Faculty University of Sumatera Utara. 
This study was performed in Mental Hospital of Province of North Sumatera, on the regulation of Medical 
Faculty of University of North Sumatera. Research time from September 1 2011 until  November 20 2011. The 
criteria inclusion are female schizofrenic patients who met the diagnostic criteria according ICD-108, age 15 to 
55 years, ideal body weight (BMI = 18.50 to 24.99), has the same severity measured by the PANSS total score> 
90 and with the provisions of sub-scale score of ≥ 5 positive on one or more of the following PANSS items: 
delusions, thought processes chaos, hallucinatory behavior, suspicion / paranoid,at the acute phase. Written 
informed consent was obtained from all participants after giving a full explanation of the study protocol. 
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Autoanamnese undergo direct interview using a measurement scale PANSS to compare the effects of quetiapine 
and haloperidol in reducing positive symptoms in female schizophrenic patients.  
 
2.1 Assessment and Rating 
First, the patient will be measured using the PANSS severity, then the patient will undergo the ICD-10 and in the 
acute phase before getting treatment intervention. Twenty samples will be interfered with risperidone. Every two 
weeks the patient was observed and the dose titrated. The initial dose of quetiapine 150 mg / day every 2 weeks 
was observed and the dose titrated slowly until it reached 750 mg/day for 8 weeks. If the patient does not achieve 
clinical remission after 2 weeks of administration of risperidone, the patient was considered unresponsive to 
treatment with risperidone and excluded in this study. Furthermore, the patients will be given treatment with 
other antipsychotics. During the study, additional drugs may be administered to the patient is limited to 
trihexypenidyl a dose of 4 mg/day (split into two feedings). Then re-examination in the eight week, to assess the 
severity of schizophrenic patients used a scale of measurement to assess the PANSS score. For The control group 
using the initial dose of haloperidol 5 mg/day and slowly it reached 20 mg/day for 8 week. Then re-examination 
in the eight week, to assess the severity of schizophrenic patients used a scale of measurement to assess the 
PANSS. Assessment results PANSS scores at baseline before treatment with after the eighth week of treatment 
assessed whether there was an improvement.   
 
2.2 Statistical Analysis 
Analytical studies with experimental approaches One group pre test - post test design to see the effect of 
improving the effectiveness of quetiapine and haloperidol  on scores Positive and Negative Syndrome Scale 
(PANSS) in schizophrenic female patients. The results of PANS scores at the time before and after treatment 
incorporated into the data and then tabulated and processed. Statistical analysis using the chi-square. Processing 
and data analysis using SPSS statistical test. From the independent t-test values seen no significant difference 
between the mean value comparison 2 groups of quetiapine and haloperidol before and after p = 0.001. 
 
3. Result  
Table 1. Distribution of the study sample based on demographic characteristics. 
     quetiapine   haloperidol         P 
        n (%)   n (%) 
Age group 
15-       8    40   4 20    0,250 
25-       5       25   3 15 
35-       4  20   6 30 
45- 55       3 15   7 35 
Total      20 100   20 100 
 
From table 1. above, it can be seen that the distribution of the study sample by age group with the most samples 
for the group that received treatment quetiapine is the age group of 15-24 of 8 samples (40%) and having at least 
a sample is the age group of 45-55 for 3 samples (15%), the group receiving haloperidol therapy that has the 
most samples were ages 45-55 at 7 samples (35%) and having at least a sample is the age group of 25-35 for 3 
samp (15%), using obtained chi square test P = 0.250 (P> 0.05) found no significant difference in the proportion 
of group  therapy based on age. 
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Table .2.  Distribution of samples Quetiapine and haloperidol treatment groups based on demographic 
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From the table 2. above, can be seen in the quetiapine treatment groups based on the level of education that has 
the most samples are primary school education level  and high school with a sample of each of the 7 samples 
(35%) while the lowest group of college education with a sample of 2 (10%). while in the haloperidol group has 
the most sampled at a rate of 10 samples of high school education (50%), while the sample at least at the level of 
higher education that is 3 samples (15%). By using the chi square test P value = 0.507 obtained (P> 0.05) found 
no significant differences in the proportion of education. 
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From the table 4.3. The above can be seen in the interaction between quetiapine and haloperidol treatment on 
demographic characteristics based on marital status. In the quetiapine group most unmarried status of 11 samples 
(55%), whereas the haloperidol group most at the marital status of 12 samples (60%), the chi square test P value 
= 0.342 obtained (P> 0.05) . There is no significant difference in the proportion of quetiapine and haloperidol 
groups based on marital status. 
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Table 4.  Characteristic positive PANSS Score at  week- 1 group  therapy Quetiapine and Haloperidol 
  
PANSS Score 
 Therapy  
 
Quetiapine  Haloperidol  




        
PANSS positif  20 23.05 1,39 20 22,15 1,92 0,128 
 
On the measurement of positive PANSS scores at the fifth day were found positive PANSS scores for quetiapine 
treatment groups with a mean of 26.6 (SD ± 1.99) and PANSS positive scores for haloperidol treatment group 
mean value of 26.05 (SD ± 1.19 ), P = 0.226 (P> 0.05). There were no significant differences in PANSS positive 
scores on the fifth day by the intervention group. 
 
Table 5. Characteristic positive PANSS Score at  week- 2 group  therapy Quetiapine and Haloperidol 
  
PANSS 
 Terapi  
 
Quetiapine  Haloperidol  




        
PANSS positif  20 20,3 1,65 20 19,5 1,95 0,361 
 
On the measurement of the PANSS positive score in the second week were found positive PANSS scores for 
quetiapine treatment groups with a mean of 20.3 (SD ± 1.65) and PANSS positive scores for haloperidol 
treatment group mean value of 19.5 (SD ± 1.95 ), P = 0.361 (P> 0.05). There were no significant differences in 
PANSS positive scores on the second week based intervention group. 
 
Table 6. Characteristic positive PANSS Score at week- 3 group therapy Quetiapine and Haloperidol  
  
PANSS 
 Terapi  
 
   Quetiapine  Haloperidol  




        
PANSS positif  20 14,65 1,13 20 16,15 1,42 0,001 
On the measurement of the PANSS positive score in the third week found positive PANSS scores for quetiapine 
treatment groups with a mean of 14.65 (SD ± 1.13) and PANSS positive scores for haloperidol treatment group 
mean value of 16.15 (SD ± 1.42 ), P = 0.001 (P <0.05). Obtained positive PANSS scores were significant 
differences in the third week based group intervention. 
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Table 7.  Characteristic positive PANSS Score at  week - 4 group therapy Quetiapine and Haloperidol  
  
PANSS Scale 
 Therapy  
 
Quetiapine  Haloperidol  




        
PANSS positif  20 12,85 1,18 20 13,70 1,41 0,034 
 
On the measurement of positive PANSS score at week four were found positive PANSS scores for quetiapine 
treatment groups with a mean of 12.85 (SD ± 1.18) and PANSS positive scores for haloperidol treatment group 
mean value of 13.70 (SD ± 1.41 ), P = 0.034 (P <0.05). Scores obtained significant differences in PANSS 
positive in the fourth week based group intervention. 
  
4. Discussion 
This study shows that the effectiveness of quetiapine may improve positive symptoms rates of female 
schizophrenic patients using a measurement PANSS scale. The results of this study show quetiapine more better 
than haloperidol to improve positive symptoms with PANSS scalecan’t directly express the effectiveness of 
risperidone may improve cognitive function or as a whole can be assessed that the schizophrenic patients, the 
better the better the prognosis will also cognitive function. 
 This showed no difference in PANSS scores level sub positive scale in the provision of quetiapine 
compared to haloperidol administration. This is similar to the results  the gain is not significantly different to the 
score of the PANSS positive sub-scale in the fifth and seventh ( Hidayati,2009). 
 
5. Conclusion 
From the this study it was found that risperidone effectively improves positive symptoms in female 
schizophrenic patients based on the presence of significant differences in PANSS Score(p = 0.034)) 
 Treatment of schizophrenic patients should pay attention to positive symptoms. Provision of atypical 
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